Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
Eur J Cancer
    February 2026
  1. KISHINANI M, Girish M, Sinha S, Donakonda S, et al
    Single-cell systems network and machine learning dissection of ferroptosis in recurrent glioblastoma highlights astrocytic ZFP36 as a therapeutic hub for network medicine repurposing.
    Eur J Cancer. 2026;237:116591.
    >> Share

    January 2026
  2. LE RHUN E, Sain D, van den Bent M, Franceschi E, et al
    Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma.
    Eur J Cancer. 2026;235:116225.
    >> Share

    December 2025
  3. ISLAM MT, Yang F, Komladzei S, Akhter M, et al
    Integrative machine learning reveals hidden and emerging co-regulatory gene networks for multi-phase glioblastoma outcome prediction.
    Eur J Cancer. 2025;234:116197.
    >> Share

  4. BORREGO MR, Lopez-Bravo DP, Vila MM, Perez-Garcia JM, et al
    Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study.
    Eur J Cancer. 2025;233:116161.
    >> Share

    October 2025
  5. VAN LINDER BMH, Brandsma D, Verhoeven E, Jongejan L, et al
    Improving the diagnosis of leptomeningeal metastases by molecular profiling of cell-free DNA from cerebrospinal fluid.
    Eur J Cancer. 2025;229:115783.
    >> Share

  6. POSTMUS D, Cornelissen JJ, Bogaerts J, Roes KC, et al
    Beyond traditional endpoints: A multi-state modelling approach to integrating morbidity and mortality in cancer treatments evaluation.
    Eur J Cancer. 2025;228:115704.
    >> Share

    September 2025
  7. MCCABE M, Rossi S, Cerza F, Massimino M, et al
    Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results.
    Eur J Cancer. 2025;227:115661.
    >> Share

    July 2025
  8. CAILLOT R, Blom A, Lebbe C, Da Meda L, et al
    Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.
    Eur J Cancer. 2025;227:115637.
    >> Share

    June 2025
  9. MANDALA M, Amaral T, Rutkowski P, Sergi MC, et al
    Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.
    Eur J Cancer. 2025;225:115567.
    >> Share

    May 2025
  10. BLOEM M, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, et al
    Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.
    Eur J Cancer. 2025;223:115514.
    >> Share

  11. MORFOUACE M, Bielle F, Razis E, Estrade F, et al
    Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.
    Eur J Cancer. 2025;223:115493.
    >> Share

  12. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
    Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
    Eur J Cancer. 2025;220:115377.
    >> Share

  13. DESAI AV, Bagchi A, Armstrong AE, van Tilburg CM, et al
    Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions.
    Eur J Cancer. 2025;220:115308.
    >> Share

    April 2025
  14. LEIBETSEDER A, Berghoff AS
    Response to letter commenting on "Association of pregnancy with tumour progression in patients with glioma".
    Eur J Cancer. 2025 Apr 9:115411. doi: 10.1016/j.ejca.2025.115411.
    >> Share

  15. DANG C, Liu P, Yu X
    Letter Re: Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025 Apr 4:115410. doi: 10.1016/j.ejca.2025.115410.
    >> Share

    March 2025
  16. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    >> Share

    January 2025
  17. LEIBETSEDER A, Mair MJ, Serra AS, Spiro Z, et al
    Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025;218:115259.
    >> Share

  18. PEDERSEN S, Johansen EL, Hojholt KL, Pedersen MW, et al
    Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).
    Eur J Cancer. 2025;217:115253.
    >> Share

  19. PEARSON AD, Mueller S, Filbin MG, Grill J, et al
    Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Eur J Cancer. 2025;217:115230.
    >> Share

    December 2024
  20. DUERINCK J, Karschnia P, Broekman M, Gempt J, et al
    Addressing the role of surgery in brain tumour trials: A report from the neurosurgery committee of the EORTC brain tumour group.
    Eur J Cancer. 2024;216:115198.
    >> Share

  21. DI CARLO D, Annereau M, Vignes M, Denis L, et al
    Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: Results of an international academia-driven compassionate use program.
    Eur J Cancer. 2024;216:115165.
    >> Share

  22. DE GROOT FA, Dekker TJA, Doorduijn JK, Bohringer S, et al
    Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies.
    Eur J Cancer. 2024;213:115068.
    >> Share

    November 2024
  23. OORT Q, Reijneveld JC, Sikkes SAM, Koekkoek JAF, et al
    Instrumental activities of daily living in neuro-oncology: International validation of the EORTC IADL-BN32 questionnaire.
    Eur J Cancer. 2024;212:114335.
    >> Share

    September 2024
  24. TSUCHIYA-KAWANO Y, Shiraishi Y, Tanaka K, Tachihara M, et al
    Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).
    Eur J Cancer. 2024;212:115052.
    >> Share

  25. GERRITSEN JKW, Mekary RA, Pisica D, Zwarthoed RH, et al
    Onco-functional outcome after resection for eloquent glioblastoma (OFO): A propensity-score matched analysis of an international, multicentre, cohort study.
    Eur J Cancer. 2024;212:114311.
    >> Share

    July 2024
  26. LE RHUN E, Weller M, Anders C, Larkin J, et al
    "Symptomatic" melanoma brain metastases: A call for clear definitions and adoption of standardized tools.
    Eur J Cancer. 2024;208:114202.
    >> Share

    June 2024
  27. CHEW SM, Ferraro E, Safonov A, Chen Y, et al
    Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes.
    Eur J Cancer. 2024;207:114175.
    >> Share

    May 2024
  28. TRAMA A, Botta L, Stiller C, Visser O, et al
    Survival of European adolescents and young adults diagnosed with cancer in 2010-2014.
    Eur J Cancer. 2024;202:113558.
    >> Share

    April 2024
  29. LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al
    Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475].
    Eur J Cancer. 2024 Apr 23:114066. doi: 10.1016/j.ejca.2024.114066.
    >> Share

  30. KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al
    Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
    Eur J Cancer. 2024;201:113951.
    >> Share

    March 2024
  31. PICCA A, Touat M, Belin L, Gourmelon C, et al
    REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
    Eur J Cancer. 2024;202:114034.
    >> Share

  32. THOMAS-JOULIE A, Tran S, El Houari L, Seyve A, et al
    Prognosis of glioblastoma patients improves significantly over time interrogating historical controls.
    Eur J Cancer. 2024;202:114004.
    >> Share

  33. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
    Eur J Cancer. 2024 Mar 8:113981. doi: 10.1016/j.ejca.2024.113981.
    >> Share

    February 2024
  34. STRATMANN JA, Althoff FC, Doebel P, Rauh J, et al
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Eur J Cancer. 2024;201:113911.
    >> Share

  35. KOCHANEK C, Gilde C, Zimmer L, Ugurel S, et al
    Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
    Eur J Cancer. 2024;198:113508.
    >> Share

    January 2024
  36. MANDALA M, Lorigan P, Sergi MC, Benannoune N, et al
    Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
    Eur J Cancer. 2024;199:113542.
    >> Share

  37. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
    Eur J Cancer. 2024;199:113531.
    >> Share

  38. LI Z, Song Y, Farrukh Hameed NU, Yuan S, et al
    Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial.
    Eur J Cancer. 2024;199:113528.
    >> Share

  39. HABRINGER S, Demel UM, Fietz AK, Lammer F, et al
    A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
    Eur J Cancer. 2024;196:113436.
    >> Share

  40. WATANABE S, Furuya N, Nakamura A, Shiihara J, et al
    A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Eur J Cancer. 2024;197:113469.
    >> Share

    December 2023
  41. LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al
    Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
    Eur J Cancer. 2023;198:113475.
    >> Share

  42. STEMMER A, Margalit O, Serpas V, Strauss G, et al
    Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Eur J Cancer. 2023;198:113495.
    >> Share

    October 2023
  43. LIU D, Wang J
    Re: Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials.
    Eur J Cancer. 2023 Oct 27:113385. doi: 10.1016/j.ejca.2023.113385.
    >> Share

    September 2023
  44. ROSSIDES M, Mogensen H, Kampitsi CE, Talback M, et al
    Parental occupational exposure to metals and risk of cancer in the offspring: A register-based case-control study from Sweden.
    Eur J Cancer. 2023;191:113243.
    >> Share

    August 2023
  45. DOHM AE, Nakashima JY, Kalagotla H, Jiang SX, et al
    Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
    Eur J Cancer. 2023;192:113287.
    >> Share

  46. SOUSSAIN C, Malaise D, Choquet S, Ghesquieres H, et al
    Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral L
    Eur J Cancer. 2023;189:112909.
    >> Share

    June 2023
  47. PADOVAN M, Maccari M, Bosio A, De Toni C, et al
    Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
    Eur J Cancer. 2023;191:112959.
    >> Share

  48. REIJNEVELD JC, Machingura A, Coens C, Taphoorn MJB, et al
    Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Trea
    Eur J Cancer. 2023;190:112946.
    >> Share

    May 2023
  49. DESMOULINS I, Bellio H, Mejean N, Truntzer C, et al
    Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.
    Eur J Cancer. 2023;187:161-163.
    >> Share

  50. HERTLER C, Felsberg J, Gramatzki D, Le Rhun E, et al
    Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
    Eur J Cancer. 2023 May 8:S0959-8049(23)00230-7. doi: 10.1016/j.ejca.2023.
    >> Share

    April 2023
  51. ALAFANDI A, van Garderen KA, Klein S, van der Voort SR, et al
    Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status.
    Eur J Cancer. 2023;188:122-130.
    >> Share

  52. MANACORDA S, Carmena MT, Malone C, Linh Le HM, et al
    Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.
    Eur J Cancer. 2023;188:98-107.
    >> Share

    March 2023
  53. CARAMANNA I, Reijneveld JC, van de Ven PM, van den Bent M, et al
    Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials.
    Eur J Cancer. 2023;186:38-51.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016